Insight Molecular Diagnostics (IMDX)
NASDAQ:IMDX
Want to see IMDX full AI Analyst Report?
IMDX Stock Chart & Stats
$3.17
--
Market closed
$3.17
--
Day’s Range― - ―
52-Week Range$2.33 - $8.51
Previous CloseN/A
VolumeN/A
Average Volume (3M)42.75K
Market Cap
$168.24M
Enterprise Value$114.85M
Total Cash (Recent Filing)$11.58M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
May 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.65
Shares Outstanding32,167,976
10 Day Avg. Volume47,668
30 Day Avg. Volume42,754
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-7.26
Price to Sales (P/S)56.37
P/FCF Ratio-9.01
Enterprise Value/Market Cap0.68
Enterprise Value/Revenue28.32
Enterprise Value/Gross Profit604.46
Enterprise Value/Ebitda-4.05
Forecast
1Y Price Target
$10.50Price Target Upside231.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$2.59M
Bulls Say, Bears Say
Bulls Say
Clinical PerformanceAnalyst highlights independent validation showing the test can deliver patient results within a single day and aligns with leading sequencing methods, supporting clinical reliability and streamlined hospital workflows.
Commercial Partnerships And DistributionAnalyst points to the partnership with Bio‑Rad and the kitted transplant test strategy as a commercial advantage that could accelerate global adoption and enable local labs to run tests and capture revenue.
Regulatory ApprovalAnalyst notes submission of GraftAssureDx for FDA clearance creates a clear pathway toward formal commercialization and broader market access.
Bears Say
Competitive LandscapeAnalyst cautions that strong competition from established transplant testing firms and the need to build an effective global commercial strategy could slow market penetration and revenue growth.
Funding And Cash BurnAnalyst warns that increased spending to support commercialization and current cash use could necessitate additional financing or tighter capital allocation, creating funding risk for operations.
Regulatory Review UncertaintyAnalyst cautions the FDA de novo review process can be paused by questions, introducing potential delays and uncertainty for regulatory approval timelines.
Insight Molecular Diagnostics News
IMDX FAQ
What was Insight Molecular Diagnostics’s price range in the past 12 months?
Insight Molecular Diagnostics lowest stock price was $2.33 and its highest was $8.51 in the past 12 months.
What is Insight Molecular Diagnostics’s market cap?
Insight Molecular Diagnostics’s market cap is $168.24M.
When is Insight Molecular Diagnostics’s upcoming earnings report date?
Insight Molecular Diagnostics’s upcoming earnings report date is May 18, 2026 which is in 12 days.
How were Insight Molecular Diagnostics’s earnings last quarter?
Insight Molecular Diagnostics released its earnings results on Mar 26, 2026. The company reported -$0.72 earnings per share for the quarter, missing the consensus estimate of -$0.238 by -$0.482.
Is Insight Molecular Diagnostics overvalued?
According to Wall Street analysts Insight Molecular Diagnostics’s price is currently Undervalued.
Does Insight Molecular Diagnostics pay dividends?
Insight Molecular Diagnostics does not currently pay dividends.
What is Insight Molecular Diagnostics’s EPS estimate?
Insight Molecular Diagnostics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Insight Molecular Diagnostics have?
Insight Molecular Diagnostics has 32,167,976 shares outstanding.
What happened to Insight Molecular Diagnostics’s price movement after its last earnings report?
Insight Molecular Diagnostics reported an EPS of -$0.72 in its last earnings report, missing expectations of -$0.238. Following the earnings report the stock price went down -13.382%.
Which hedge fund is a major shareholder of Insight Molecular Diagnostics?
Currently, no hedge funds are holding shares in IMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Insight Molecular Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (231.23% Upside)
$10.50 (231.23% Upside)
Hedge Fund Trend
Decreased
By 44.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $5.7M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
69.71%
12-Months-Change
Fundamentals
Return on Equity
684.60%
Trailing 12-Months
Asset Growth
-26.58%
Trailing 12-Months
Company Description
Insight Molecular Diagnostics
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
IMDX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights major strategic and operational progress: submission of GraftAssureDx to the FDA, robust early clinical engagement (registry and head-to-head data), successful $26M financing with strategic investor support, a clear U.S. reimbursement pathway (Medicare rate and MolDx Z-code submission), and a defined plan to expand into heart transplants via a 510(k) pathway. Near-term risks include low expected lab revenue in Q1, front-loaded cash burn and higher quarterly spending, an intangible write-down on oncology assets, and reimbursement/operational complexity in EU/UK and MAC territories. Overall, the positives—regulatory milestone, strong external validation, funding, and an explicit commercialization plan—outweigh the near-term financial and market-access risks, supporting an optimistic outlook while acknowledging execution risk.View all IMDX earnings summariesIMDX Stock 12 Month Forecast
Average Price Target
$10.50
▲(231.23% Upside)
Technical Analysis
Ownership Overview
80.04% Insiders
1.90% Mutual Funds
0.81% Other Institutional Investors
15.51% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---